Re: Yawn

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

tada

Rank: President [?]

Points: 7750 [?]

Votes: 40 Score: 3.4 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Yawn

in response to

Yawn

BearDownAZ

posted on May 24, 2017 01:06PM

If the info presented to the group of brokers 23 Feb was correct it would now be about 4.5 months since the first cohort of the combination ZEN3694 and enzilutamide have been administered to patients. Maybe we will get an update on that unless they are keeping the info quiet for competative reasons.